Ritika Gera1, Leon Mokbel1, Wen G Jiang2, Kefah Mokbel3. 1. The London Breast Institute, The Princess Grace Hospital, London, U.K. 2. Metastasis & Angiogenesis Research Group, University Department of Surgery, Cardiff University School of Medicine, Cardiff University, Cardiff, U.K. 3. The London Breast Institute, The Princess Grace Hospital, London, U.K. kefahmokbel@hotmail.com.
Abstract
BACKGROUND: Cyclin-dependent kinase 2-associated protein 1 (CDK2AP1) interacts with CDK2AP2, modulates the actions of transforming growth factor-B1, cyclin-dependent kinase 2 and retinoblastoma protein, and closely interacts with micro-RNA21 and micro-RNA25. Our objective was to determine if CDK2AP1 mRNA expression levels were consistent with tumour-suppressive functions in breast cancer. MATERIALS AND METHODS: A total of 134 samples were analysed. CDK2AP1 mRNA levels were measured using quantitative polymerase chain reaction (RT-PCR) and normalised against glyceraldehyde 3-phosphate dehydrogenase mRNA. Levels in breast cancer and adjacent non-cancerous breast tissue were analysed against pathological and clinical parameters (TNM staging, survival over a 10-year follow-up period). RESULTS: Normalised CDK2AP1 expression was 38-fold higher in adjacent non-cancerous breast tissue than in breast cancer. CDK2AP1 expression in disease-free patients at 10 years was more than threefold that of patients who died of breast cancer. However, neither of these differences in expression levels reached statistical significance. CDK2AP1 mRNA levels were higher in TNM1 compared to TNM3 (p=0.016) and with TNM4 (p=0.016). There were no significant associations between CDK2AP1 expression and estrogen receptor status, tumour grade and tumour type. There was no significant difference in overall survival between patients with high and those with low CDK2AP1 mRNA levels after a median follow-up of 10 years (Kaplan-Meier analysis, p=0.872). CONCLUSION: To our knowledge, this is the first study in the literature to examine the mRNA expression of CDK2AP1 in human breast cancer over a long-term follow-up period. A compelling relationship exists between high CDK2AP1 mRNA expression and lower TNM classification of breast cancer, which is consistent with CDK2AP1 having a tumour-suppressive function. Copyright
BACKGROUND:Cyclin-dependent kinase 2-associated protein 1 (CDK2AP1) interacts with CDK2AP2, modulates the actions of transforming growth factor-B1, cyclin-dependent kinase 2 and retinoblastoma protein, and closely interacts with micro-RNA21 and micro-RNA25. Our objective was to determine if CDK2AP1 mRNA expression levels were consistent with tumour-suppressive functions in breast cancer. MATERIALS AND METHODS: A total of 134 samples were analysed. CDK2AP1 mRNA levels were measured using quantitative polymerase chain reaction (RT-PCR) and normalised against glyceraldehyde 3-phosphate dehydrogenase mRNA. Levels in breast cancer and adjacent non-cancerous breast tissue were analysed against pathological and clinical parameters (TNM staging, survival over a 10-year follow-up period). RESULTS: Normalised CDK2AP1 expression was 38-fold higher in adjacent non-cancerous breast tissue than in breast cancer. CDK2AP1 expression in disease-free patients at 10 years was more than threefold that of patients who died of breast cancer. However, neither of these differences in expression levels reached statistical significance. CDK2AP1 mRNA levels were higher in TNM1 compared to TNM3 (p=0.016) and with TNM4 (p=0.016). There were no significant associations between CDK2AP1 expression and estrogen receptor status, tumour grade and tumour type. There was no significant difference in overall survival between patients with high and those with low CDK2AP1 mRNA levels after a median follow-up of 10 years (Kaplan-Meier analysis, p=0.872). CONCLUSION: To our knowledge, this is the first study in the literature to examine the mRNA expression of CDK2AP1 in humanbreast cancer over a long-term follow-up period. A compelling relationship exists between high CDK2AP1 mRNA expression and lower TNM classification of breast cancer, which is consistent with CDK2AP1 having a tumour-suppressive function. Copyright
Authors: Joongho Shin; Ziqian Yuan; Kenneth Fordyce; Prashanth Sreeramoju; Tara S Kent; John Kim; Victor Wang; David Schneyer; Thomas K Weber Journal: Surgery Date: 2007-08 Impact factor: 3.982
Authors: Miaofen G Hu; Guo-Fu Hu; Yong Kim; Takanori Tsuji; Jim McBride; Philip Hinds; David T W Wong Journal: Cancer Res Date: 2004-01-15 Impact factor: 12.701
Authors: Anthony J Trimboli; Koichi Fukino; Alain de Bruin; Guo Wei; Lei Shen; Stephan M Tanner; Nicholas Creasap; Thomas J Rosol; Michael L Robinson; Charis Eng; Michael C Ostrowski; Gustavo Leone Journal: Cancer Res Date: 2008-02-01 Impact factor: 12.701
Authors: Waranun Buajeeb; Xue Zhang; Hiroe Ohyama; David Han; Rudee Surarit; Yong Kim; David T W Wong Journal: Biochem Biophys Res Commun Date: 2004-03-19 Impact factor: 3.575
Authors: Wen G Jiang; Gareth Watkins; Jane Lane; Giles H Cunnick; Anthony Douglas-Jones; Kefah Mokbel; Robert E Mansel Journal: Clin Cancer Res Date: 2003-12-15 Impact factor: 12.531